Paradigm Thera, Takeda Pharmaceuticals Co. Ltd. deal

Takeda will acquire Paradigm for undisclosed terms. The deal gives Takeda target identification and medicinal chemistry capabilities in pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity. Takeda's core therapeutic focus areas include oncology and urologic diseases, CNS diseases, life style-related diseases, and gastroenterology. ...